India ramps up GLP‑1 surveillance

India’s drug regulator has moved from warning to sweeping checks after a flood of low‑cost GLP‑1 drugs began appearing across pharmacies, online warehouses and slimming clinics. (static.pib.gov.in) Teams from the Drugs Controller General of India and state regulators inspected dozens of supply‑chain points this month to find whether prescription rules, advertising bans and storage requirements were being flouted. (economictimes.indiatimes.com) The government says the actions respond to evidence of unauthorised sales and promotional claims aimed at consumers, not clinicians. (cnbctv18.com) Why now: patents on semaglutide — the molecule behind blockbuster brands used for diabetes and obesity — have lapsed in key jurisdictions, and Indian manufacturers have rolled out multiple generic versions and oral formulations. (businesstoday.in) Regulators say the rapid arrival of cheaper options has made the drugs widely available beyond specialist clinics, increasing the risk of misuse. (medicaldialogues.in) GLP‑1 receptor agonists work by mimicking an intestinal hormone that increases insulin release, reduces glucagon and slows gastric emptying; that combination lowers blood sugar and suppresses appetite. (economictimes.indiatimes.com) Those same mechanisms cause predictable adverse effects — nausea and vomiting, delayed gastric emptying, and in some cases pancreatitis, gallbladder events and kidney injury — which make medical supervision important. (businesstoday.in) The regulatory response has three practical threads for drug‑safety programs. First, enforcement: inspectors have issued notices and warned of licence cancellation, fines and legal action for unauthorised sale or misleading promotion, signalling faster administrative penalties for non‑compliance. (newindianexpress.com) Second, prescribing controls: authorities are reiterating that GLP‑1 medicines are prescription‑only and urging that only appropriately qualified specialists manage therapy decisions. (economictimes.indiatimes.com) Third, market surveillance: audits targeted e‑commerce warehouses, wholesalers, retail pharmacies and wellness clinics where off‑label promotions and easy consumer access have been reported. (static.pib.gov.in) For a company running post‑market safety, those threads mean concrete steps. Expect regulators to demand rapid adverse‑event reports tied to off‑label or consumer‑direct sales, to scrutinize promotional materials for consumer‑facing claims, and to push upstream into distribution controls and batch‑level tracking. Strengthen signal detection for GI complications, pancreatitis and renal events and add monitoring streams that capture social‑media promotion and online pharmacy listings. (cnbctv18.com) The most tangible detail from the government announcement: officials say they audited 49 entities — a mix of online pharmacy warehouses, drug wholesalers, retailers and wellness or slimming clinics — and have sent notices where practices appeared to violate prescription and advertising rules. (static.pib.gov.in)